<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03622333</url>
  </required_header>
  <id_info>
    <org_study_id>PO18020</org_study_id>
    <nct_id>NCT03622333</nct_id>
  </id_info>
  <brief_title>Clinic, Pathologic and Genetic Characterization of Patients With Familial Carcinoid Tumors (Study From the GTE, Groupe d'étude Des Tumeurs Endocrines)</brief_title>
  <official_title>Clinic, Pathologic and Genetic Characterization of Patients With Familial Carcinoid Tumors (Study From the GTE, Groupe d'étude Des Tumeurs Endocrines)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHU de Reims</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHU de Reims</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Small intestine carcinoid tumors are rare. Small intestine Familial Carcinoid Tumors (FCT)
      are defined by the occurrence of at least 2 cases of this tumor type in first- or
      second-degree relatives. The estimated prevalence of FCT is 2.6%-3.7% in patients with small
      intestine carcinoid tumors. Because of its rarity, epidemiologic, clinic and pathologic
      features of FCT have been scarcely described. Molecular abnormalities associated with FCT
      have been poorly explored. Constitutional genetic factors predisposing to FCT have not been
      discovered to date. Only one abnormality (mutation of the IPMK gene) has been reported in one
      FCT family only, but not found in other series.

      The main objective of this study is to identify the constitutional factors predisposing to
      small-intestine FCT (and other midgut localizations: ascending colon and appendix). The
      secondary objectives are to describe the clinic and pathologic features associated with FCT.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 28, 2018</start_date>
  <completion_date type="Anticipated">November 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 28, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Deletion</measure>
    <time_frame>day 0</time_frame>
    <description>Quantitative Constitutional genetic alterations detected by comparative genomic hybridization (CGH array)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>duplication</measure>
    <time_frame>Day 0</time_frame>
    <description>Quantitative Constitutional genetic alterations detected by comparative genomic hybridization (CGH array)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>amplification</measure>
    <time_frame>Day 0</time_frame>
    <description>Quantitative Constitutional genetic alterations detected by comparative genomic hybridization (CGH array)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>mutation</measure>
    <time_frame>Day 0</time_frame>
    <description>qualitative Constitutional genetic alterations detected by NGS (Next Generation Sequencing)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Small Intestinal Carcinoid Tumors</condition>
  <arm_group>
    <arm_group_label>Familial Carcinoid Tumors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients with proven Familial Carcinoid Tumors</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Research of constitutional genetic alterations</intervention_name>
    <description>Tumor DNA extraction Blood sample and constitutional DNA extraction CGH-array, Exome sequencing Bio-informatic analysis</description>
    <arm_group_label>Familial Carcinoid Tumors</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        inclusion criteria :

          -  Small-intestine (or ascending colon or appendix) neuroendocrine tumor (proven
             histologically)

          -  At least one first- or second-degree relative with a small-intestine (or ascending
             colon or appendix) neuroendocrine tumor (proven histologically)

          -  Agreement to participate to the study exclusion criteria :

          -  Subjects unable to provide consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Guillaume CADIOT</last_name>
    <phone>03 26 78 84 41</phone>
    <email>gcadiot@chu-reims.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Louis DE MESTIER</last_name>
    <email>louis.demestier@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Damien JOLLY</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume CADIOT</last_name>
      <phone>03 26 78 84 41</phone>
      <email>gcadiot@chu-reims.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>February 22, 2018</study_first_submitted>
  <study_first_submitted_qc>August 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2018</study_first_posted>
  <last_update_submitted>August 17, 2018</last_update_submitted>
  <last_update_submitted_qc>August 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neuroendocrine tumors</keyword>
  <keyword>carcinoid tumors</keyword>
  <keyword>midgut</keyword>
  <keyword>small intestine</keyword>
  <keyword>genetic predisposition</keyword>
  <keyword>hereditary</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoid Tumor</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

